Company Focus
Amgen
Latest Amgen News
Pharmaceutical
US biotech major Amgen closed 7% lower on Tuesday after investors questioned whether reductions in bone mineral density might be linked to the use of its investigational obesity candidate MariTide (maridebart cafraglutide, formerly AMG 133) in a Phase I trial. 13 November 2024
Related News
Insights
Company Spotlight
A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Latest News & Features of interest to Amgen
Pharmaceutical
Dystonia is a neurological movement disorder characterized by involuntary muscle contractions that cause repetitive movements, abnormal postures, or twisting. 17 September 2024
Biotechnology
A cancer drug in-licensed by German biotech major BioNTech from China-based Biotheus could be a good one, if mid-stage results shared at the European Society for Medical Oncology (ESMO) are anything to go by. 17 September 2024
Pharmaceutical
Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate cancer. 17 September 2024
Biotechnology
Bicara Therapeutics, a biotech focused on developing bifunctional therapies for solid tumors, has closed its initial public offering, raising approximately $362 million. 17 September 2024
Biotechnology
Swiss pharma giant has shared a well-timed updated analysis from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2024 16 September 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
Pharmaceutical
German pharma major Bayer today released results from the Phase III ARANOTE trial at the European Society for Medical Oncology (ESMO) taking place in Spain. 16 September 2024
Pharmaceutical
Swiss pharma giant has shared a well-timed updated analysis from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2024. 16 September 2024
Pharmaceutical
The Gastrointestinal Drugs Advisory Committee (GIDAC) of the US Food and Drug Administration (FDA) met on Friday to discuss Intercept Pharmaceuticals’ supplemental New Drug Application (sNDA) for Ocaliva (obeticholic acid, OCA). 16 September 2024
Biotechnology
As ever, US pharma giant Merck & Co has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) at this year’s meeting of the European Society for Medical Oncology (ESMO). 16 September 2024
Latest In Brief for Amgen
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Latest Relevant Ones To Watch News
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
13 November 2024
29 October 2024
28 October 2024
26 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze